

Zydelig REMS

FDA REQUIRED UPDATED REMS SAFETY INFORMATION

Boxed Warning Risk of:

- **Fatal and/or serious hepatotoxicity - updated**
- **Fatal and/or serious and severe diarrhea or colitis - updated**
- **Fatal and/or serious pneumonitis**
- **Fatal and/or serious infections - updated**
- **Fatal and serious intestinal perforation**

January 2018

Dear <Name>:

The FDA has required Gilead Sciences to distribute this safety notice to the [Professional Organization] as part of the Zydelig REMS (**R**isk **E**valuation and **M**itigation **S**trategy). The **incidence rates of fatal and serious toxicities have been updated in the Boxed Warning** for Zydelig. We request that you distribute this information to your members about the following serious risks of Zydelig:

WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS and INTESTINAL PERFORATION

- Fatal and/or serious hepatotoxicity occurred in 16% to 18% of ZYDELIG-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue ZYDELIG.
- Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of ZYDELIG-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue ZYDELIG.
- Fatal and/or serious pneumonitis occurred in 4% of ZYDELIG-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue ZYDELIG.
- Fatal and/or serious infections occurred in 21% to 48% of ZYDELIG-treated patients. Monitor for signs and symptoms of infection. Interrupt ZYDELIG if infection is suspected.
- Fatal and serious intestinal perforation can occur in ZYDELIG-treated patients across clinical trials. Discontinue ZYDELIG if intestinal perforation is suspected.

The updated incidence rates of fatal and serious toxicities in the Zydelig Boxed Warning reflect data from patients treated with Zydelig in combination with rituximab or with unapproved combination therapies.

Please see the enclosed [Zydelig REMS Fact Sheet](#), a non-promotional fact sheet reviewed by the FDA, for more detailed safety information. Please encourage your members to provide the [Zydelig Patient Safety Information Card](#) to all patients. This card, additional copies of the fact sheet, and other important information are available at: www.ZydeligREMS.com.

Zydelig is a kinase inhibitor indicated for the treatment of patients with:

- Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities

Zydelig REMS

- Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies
- Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies

Limitation of use:

Zydelig is not indicated and is not recommended for first-line treatment of any patient. Zydelig is not indicated and is not recommended in combination with bendamustine and/or rituximab for the treatment of FL.

This letter does not contain the complete safety profile for Zydelig. Please review the enclosed Prescribing Information.

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Healthcare Providers should report all suspected adverse events associated with Zydelig to the FDA or to Gilead at 1-800-445-3235.

Sincerely,

William Guyer, Pharm.D.
Senior Vice President, Medical Affairs

From: Gilead Sciences, Inc.

To: <Name, Professional Society>

Subject: Revised Boxed Warning for Zydelig: Update to Incidence Rates of Fatal and Serious Toxicities

Zydelig® REMS

[View in Browser](#) | [Full Prescribing Information](#)



Zydelig REMS

FDA REQUIRED UPDATED REMS SAFETY INFORMATION

Boxed Warning includes the Risk of:

- **Fatal and/or serious hepatotoxicity – updated**
- **Fatal and/or serious and severe diarrhea or colitis – updated**
- **Fatal and/or serious pneumonitis**
- **Fatal and/or serious infections – updated**
- **Fatal and serious intestinal perforation**

January 2018

IMPORTANT SAFETY NOTICE

Dear <name>:

The FDA has required Gilead Sciences to distribute this safety notice to the [Professional Organization] as part of the Zydelig REMS (Risk Evaluation and Mitigation Strategy). The incidence rates of fatal and serious toxicities have been updated in the Boxed Warning for Zydelig. We request that you distribute this information to your members about the following serious risks of Zydelig.

WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION

- Fatal and/or serious hepatotoxicity occurred in 16% to 18% of ZYDELIG-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue ZYDELIG.
- Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of ZYDELIG-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue ZYDELIG.
- Fatal and/or serious pneumonitis occurred in 4% of ZYDELIG-treated patients. Monitor for pulmonary symptoms and interstitial infiltrates. Interrupt or discontinue ZYDELIG.
- Fatal and/or serious infections occurred in 21% to 48% of ZYDELIG-treated patients. Monitor for signs and symptoms of infection. Interrupt ZYDELIG if infection is suspected.
- Fatal and serious intestinal perforation can occur in ZYDELIG-treated patients across clinical trials. Discontinue ZYDELIG if intestinal perforation is suspected.

The updated incidence rates of fatal and serious toxicities in the Zydelig Boxed Warning reflect data from patients treated with Zydelig in combination with rituximab or with unapproved combination therapies.

Please see the [Zydelig REMS Fact Sheet](#), a non-promotional fact sheet reviewed by the FDA, for more detailed safety information. Please encourage your members to provide the [Zydelig Patient Safety Information Card](#) to all patients. The card, the fact sheet, and other important information are available at: www.ZydeligREMS.com.

Zydelig is a kinase inhibitor indicated for the treatment of patients with

- Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
- Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
- Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.

Limitation of use:

Zydelig is not indicated and is not recommended for first-line treatment of any patient. Zydelig is not indicated and is not recommended in combination with bendamustine and/or rituximab for the treatment of FL.

This letter does not contain the complete safety profile for Zydelig. To review the Prescribing Information, including complete **BOXED WARNING** and Medication Guide, see links below.

[Prescribing Information](#)

[Medication Guide](#)

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Healthcare Providers should report all suspected adverse events associated with Zydelig to the FDA or to Gilead at 1-800-445-3235.

Sincerely,

[signature]

William Guyer, Pharm D.
Senior Vice President, Medical Affairs

[Unsubscribe](#) | [Terms of Use](#) | [Privacy Policy](#) | [Contact Us](#)



Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA
www.ZydeligREMS.com Phone 650 574 3000 Facsimile 650 578 9264 REMS-ZYD-0037

Reference ID: 4238482

Back



From: **Gilead Sciences, Inc.** Hide
To: <Name, Professional Society>

**Revised Boxed Warning for Zydelig:
Update to Incidence Rates of Fatal
and Serious Toxicities**

January 2018 at 5:00 PM

Zydelig® REMS

[View in Browser](#) | [Full Prescribing Information](#)



Zydelig REMS

**FDA REQUIRED UPDATED
REMS SAFETY INFORMATION**

- Boxed Warning includes the Risk of:**
- **Fatal and/or serious hepatotoxicity – updated**
 - **Fatal and/or serious and severe diarrhea or colitis – updated**
 - **Fatal and/or serious pneumonitis**
 - **Fatal and/or serious infections – updated**
 - **Fatal and serious intestinal perforation**

January 2018

IMPORTANT SAFETY NOTICE

Dear <name>:

The FDA has required Gilead Sciences to distribute this safety notice to the [Professional Organization] as part of the Zydelig REMS (Risk Evaluation and Mitigation Strategy). **The incidence rates of fatal and serious toxicities have been updated in the Boxed Warning for Zydelig.** We request that you distribute this information to your members about the following serious risks of Zydelig:

- WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION**
- Fatal and/or serious hepatotoxicity occurred in 16% to 18% of ZYDELIG-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue ZYDELIG.
 - Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of ZYDELIG-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue ZYDELIG.
 - Fatal and/or serious pneumonitis occurred in 4% of ZYDELIG-treated patients. Monitor for pulmonary symptoms and interstitial infiltrates. Interrupt or discontinue ZYDELIG.
 - Fatal and/or serious infections occurred in 21% to 48% of ZYDELIG-treated patients. Monitor for signs and symptoms of infection. Interrupt ZYDELIG if infection is suspected.
 - Fatal and serious intestinal perforation can occur in ZYDELIG-treated patients across clinical trials. Discontinue ZYDELIG if intestinal perforation is suspected.

Please see the **Zydelig REMS Fact Sheet**, a non-promotional fact sheet reviewed by the FDA, for more detailed safety information. Please encourage your members to provide the **Zydelig Patient Safety Information Card** to all patients. The card, the fact sheet, and other important information are available at: www.ZydeligREMS.com.

Zydelig is a kinase inhibitor indicated for the treatment of patients with:

- Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
- Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
- Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.

Limitation of use:
Zydelig is not indicated and is not recommended for first-line treatment of any patient. Zydelig is not indicated and is not recommended in combination with bendamustine and/or rituximab for the treatment of FL.

This letter does not contain the complete safety profile for Zydelig. To review the Prescribing Information, including complete **BOXED WARNING** and Medication Guide, see links below:

[Prescribing Information](#)

[Medication Guide](#)

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Healthcare Providers should report all suspected adverse events associated with Zydelig to the FDA or to Gilead at 1-800-445-3235.

Sincerely,

[signature]

William Guyor, Pharm.D.



FDA REQUIRED Updated Safety Information for Zydelig[®] (idelalisib)

Safety information updates were made to the Boxed Warning, including incidence rates of fatal and serious toxicities.

BOXED WARNING For Zydelig (Idelalisib)

Risk of:

- **Fatal and/or serious hepatotoxicity - updated**
- **Fatal and/or serious and severe diarrhea or colitis - updated**
- **Fatal and/or serious pneumonitis**
- **Fatal and/or serious infections - updated**
- **Fatal and serious intestinal perforation**

Fatal and/or Serious Hepatotoxicity

- Fatal and/or serious hepatotoxicity occurred in 18% of patients treated with Zydelig monotherapy and 16% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies.
- Elevations in ALT or AST greater than 5 times the upper limit of normal have occurred. These findings were generally observed within the first 12 weeks of treatment and were reversible with dose interruption. After resumption of treatment at a lower dose, 26% of patients had recurrence of ALT and AST elevations. Discontinue Zydelig for recurrent hepatotoxicity.
- Avoid concurrent use of Zydelig with other drugs that may cause liver toxicity.
- Monitor ALT and AST in all patients every 2 weeks for the first 3 months of treatment, every 4 weeks for the next 3 months, then every 1 to 3 months thereafter. Monitor weekly for liver toxicity if the ALT or AST rises above 3 times the upper limit of normal until resolved. Withhold Zydelig if the ALT or AST is greater than 5 times the upper limit of normal, and continue to monitor AST, ALT and total bilirubin weekly until the abnormality is resolved.

Fatal and/or Serious and Severe Diarrhea or Colitis

- Severe diarrhea or colitis (Grade 3 or higher) occurred in 14% of patients treated with Zydelig monotherapy and 20% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies. Diarrhea can occur at any time.
- Avoid concurrent use of Zydelig and other drugs that cause diarrhea. Diarrhea due to Zydelig responds poorly to antimotility agents. Median time to resolution ranged between one week and one month across trials, following interruption of Zydelig therapy and in some instances, use of corticosteroids.

Fatal and/or Serious Pneumonitis

- Fatal and serious pneumonitis occurred in patients treated with Zydelig. Clinical manifestations included interstitial infiltrates and organizing pneumonia.
- In randomized clinical trials of combination therapies, pneumonitis occurred in 4% of patients treated with Zydelig compared to 1% on the comparator arms. Time to onset of pneumonitis ranged from <1 to 15 months. Monitor patients on Zydelig for pulmonary symptoms.
- In patients taking Zydelig who present with pulmonary symptoms such as cough, dyspnea, hypoxia, interstitial infiltrates on a radiologic exam, or a decline by more than 5% in oxygen saturation, interrupt Zydelig until the etiology has been determined.
- If symptomatic pneumonitis or organizing pneumonia is diagnosed, initiate appropriate treatment with corticosteroids and permanently discontinue Zydelig.

FDA REQUIRED Updated Safety Information for Zydelig[®] (idelalisib)

Fatal and/or Serious Infections

- Fatal and/or serious infections occurred in 21% of patients treated with Zydelig monotherapy and 48% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies. The most common infections were pneumonia, sepsis, and febrile neutropenia. Treat infections prior to initiation of Zydelig therapy.
- Monitor patients on Zydelig for signs and symptoms of infection and interrupt Zydelig for Grade 3 or higher infection.
- Serious or fatal *Pneumocystis jirovecii* pneumonia (PJP) or cytomegalovirus (CMV) occurred in <1% of patients treated with Zydelig. Provide PJP prophylaxis during treatment with Zydelig. Interrupt Zydelig in patients with suspected PJP infection of any grade, and permanently discontinue Zydelig if PJP infection of any grade is confirmed. Regular clinical and laboratory monitoring for CMV infection is recommended in patients with history of CMV infection or positive CMV serology at the start of treatment with Zydelig. Interrupt Zydelig in the setting of positive CMV PCR or antigen test until the viremia has resolved. If Zydelig is subsequently resumed, patients should be monitored by PCR or antigen test for CMV reactivation at least monthly.

Fatal and Serious Intestinal Perforation

- Fatal and serious intestinal perforation occurred in Zydelig-treated patients.
- At the time of perforation, some patients had moderate to severe diarrhea.
- Advise patients to promptly report any new or worsening abdominal pain, chills, fever, nausea, or vomiting.
- Discontinue Zydelig permanently in patients who experience intestinal perforation.

INDICATION

Zydelig is a kinase inhibitor indicated for the treatment of patients with:

- Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
- Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
- Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.

Limitations of use:

Zydelig is not indicated and is not recommended for first-line treatment of any patient. Zydelig is not indicated and is not recommended in combination with bendamustine and/or rituximab for the treatment of FL.

You are encouraged to report negative side effects of Zydelig to Gilead at 1-800-445-3235 and/or the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

This journal piece is part of the FDA-required Zydelig REMS. Visit www.ZydeligREMS.com for more information.

For complete safety information, see the Prescribing Information available at www.ZydeligREMS.com.